News brief­ing: Roche shows off more MS, NMOSD da­ta; Gala­pa­gos and Gilead clear PhI­Ia pri­ma­ry end­points but re­port SAEs

Roche’s Genen­tech an­nounced on Fri­day that it has even more da­ta to back Ocre­vus as a mul­ti­ple scle­ro­sis treat­ment.

The drug hit the mar­ket three years ago, in what CEO Sev­erin Schwan has called the most suc­cess­ful launch in the com­pa­ny’s 124-year his­to­ry.

This week­end, the biotech says it will bring new da­ta to MSVir­tu­al2020 that show Ocre­vus’ ben­e­fit in pa­tients who have re­laps­ing-re­mit­ting mul­ti­ple scle­ro­sis (RRMS), and have ex­pe­ri­enced a sub­op­ti­mal re­sponse to a pri­or dis­ease-mod­i­fy­ing ther­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER